載入...
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α(4)β(1)-integrin. In a Phase 3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) by 68% compared with placebo (p &...
Na minha lista:
| 主要作者: | |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2007
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1936307/ https://ncbi.nlm.nih.gov/pubmed/18360634 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|